🚀 VC round data is live in beta, check it out!
- Public Comps
- Acepodia
Acepodia Valuation Multiples
Discover revenue and EBITDA valuation multiples for Acepodia and similar public comparables like Sol-Gel Technologies, OmniAb, Coherus Oncology, Silence Therapeutics and more.
Acepodia Overview
About Acepodia
Acepodia Inc is a clinical stage biotechnology company engaged to develop first-in-class cell therapies by using the Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.
Founded
2017
HQ

Employees
N/A
Website
Sectors
Financials (FY)
EV
$97M
Acepodia Financials
Acepodia reported last fiscal year revenue of $13K and negative EBITDA of ($12M).
In the same fiscal year, Acepodia generated $9K in gross profit, ($12M) in EBITDA losses, and had net loss of ($16M).
Acepodia P&L
In the most recent fiscal year, Acepodia reported revenue of $13K and EBITDA of ($12M).
Acepodia expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $13K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $9K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 65% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($12M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (90359%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (177494%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (116334%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Acepodia Stock Performance
Acepodia has current market cap of $249M, and enterprise value of $97M.
Market Cap Evolution
Acepodia's stock price is $0.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $97M | $249M | (0.1%) | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAcepodia Valuation Multiples
Acepodia trades at 7243.8x EV/Revenue multiple, and (8.0x) EV/EBITDA.
Acepodia Financial Valuation Multiples
As of March 13, 2026, Acepodia has market cap of $249M and EV of $97M.
Equity research analysts estimate Acepodia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acepodia has a P/E ratio of (16.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $249M | XXX | $249M | XXX | XXX | XXX |
| EV (current) | $97M | XXX | $97M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 7243.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (8.0x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (4.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 11126.3x | XXX | XXX | XXX |
| P/E | — | XXX | (16.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Acepodia Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Acepodia Margins & Growth Rates
Acepodia's revenue in the last fiscal year declined by (97%).
Acepodia Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (97%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (90359%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (50%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 34080% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 143479% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 177559% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Acepodia Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sol-Gel Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| OmniAb | XXX | XXX | XXX | XXX | XXX | XXX |
| Coherus Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Silence Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acepodia M&A Activity
Acepodia acquired XXX companies to date.
Last acquisition by Acepodia was on XXXXXXXX, XXXXX. Acepodia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Acepodia
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAcepodia Investment Activity
Acepodia invested in XXX companies to date.
Acepodia made its latest investment on XXXXXXXX, XXXXX. Acepodia invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Acepodia
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Acepodia
| When was Acepodia founded? | Acepodia was founded in 2017. |
| Where is Acepodia headquartered? | Acepodia is headquartered in Taiwan. |
| Is Acepodia publicly listed? | Yes, Acepodia is a public company listed on Taipei Exchange. |
| What is the stock symbol of Acepodia? | Acepodia trades under 6976 ticker. |
| When did Acepodia go public? | Acepodia went public in 2023. |
| Who are competitors of Acepodia? | Acepodia main competitors are Sol-Gel Technologies, OmniAb, Coherus Oncology, Silence Therapeutics. |
| What is the current market cap of Acepodia? | Acepodia's current market cap is $249M. |
| What is the current revenue of Acepodia? | Acepodia's last fiscal year revenue is $13K. |
| What is the current EV/Revenue multiple of Acepodia? | Current revenue multiple of Acepodia is 7243.8x. |
| Is Acepodia profitable? | No, Acepodia is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.